



Docket No.: PF613TD1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Yoshimura et al.

Application No.: 10/726,148

Confirmation No.: 4267

Filed: December 2, 2003

Art Unit: 1652

For: Novel Protein and DNA Thereof

Examiner: M. Monshipouri

FIRST INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to references AA-AH listed on the attached Form PTO/SB/08A. A copy of reference AC is enclosed.

Copies of references AA-AB, and AD-AH were submitted by Applicants or cited by the Examiner in connection with U. S. Patent Application No. 09/786,256, filed May 10, 2001, to which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the file of U. S. Patent Application No. 09/786,256 for copies of references AA-AB, and AD-AH.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR § 1.104(a) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Identification of the listed reference(s) is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such

Application No.: 10/726,148

Docket No.: PF613TD1


references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Applicants respectfully request that the Examiner review the listed reference(s) and that the reference(s) be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), since this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Sciences, Inc., deposit account no. 08-3425.

Dated: May 26, 2004

Respectfully submitted,

By 
Mark J. Hyman
Registration No.: 46,789
HUMAN GENOME SCIENCES, INC.
14200 Shady Grove Road
Rockville, Maryland 20850
(240) 314-1224

Please type a plus sign (+) inside this box → ☐

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/726,148
				Filing Date	December 2, 2003
				First Named Inventor	Yoshimura et al.
				Group Art Unit	1652
				Examiner Name	Monshipouri, M.
Sheet	1	of	1	Attorney Docket Number	PF613TD1

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	AA	5,990,293		Docherty et al.	11-23-1999	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	AB	WO	97/09430		Celltech Therapeutics Ltd.	03-13-1997		

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AC	GENBANK Accession No. A61275, "Sequence 1 from Patent WO9709430," (March 1998).	
	AD	HITE, et al., "Sequence of a cDNA clone encoding the zinc metalloprotease hemorrhagic toxin e from Crotalus atrox: Evidence for signal, zymogen and disintegrin-like structures," <i>Biochemistry</i> 31:6203-6211 (1992).	
	AE	HOWARD, et al., "Molecular cloning of MADM: a catalytically active mammalian disintegrin-metalloprotease expressed in various cell types," <i>Biochem. J.</i> 317:45-50 (1996).	
	AF	KRATZSCHMAR, et al., "Metargidin, a membrane-anchored metalloprotease-disintegrin protein with an RGD integrin binding sequence," <i>J. Biol. Chem.</i> 271(9):4593-4596 (1996).	
	AG	PAINE, M.J.I. et al., "Cloning of metalloprotease genes in the carpet viper (<i>Echis pyramidum leakeyi</i>): Further members of the metalloprotease/disintegrin gene family," <i>Eur. J. Biochem.</i> 224:483-488 (1994).	
	AH	WOLFSBERG, T.J. et al., "ADAM, a novel family of membrane proteins containing a disintegrin and metalloprotease domain: Multipotential functions in cell-cell and cell-matrix interactions," <i>J. Cell Biol.</i> 131:275-278 (1995).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ See attached Kinds of U.S. Patent Documents. ⁴ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.